000164052 001__ 164052
000164052 005__ 20240229123203.0
000164052 0247_ $$2doi$$a10.1007/s11307-020-01548-y
000164052 0247_ $$2pmid$$apmid:33063132
000164052 0247_ $$2ISSN$$a1536-1632
000164052 0247_ $$2ISSN$$a1860-2002
000164052 0247_ $$2altmetric$$aaltmetric:115614092
000164052 037__ $$aDKFZ-2020-02220
000164052 041__ $$aeng
000164052 082__ $$a570
000164052 1001_ $$0P:(DE-HGF)0$$aRistau, J.$$b0
000164052 245__ $$aImpact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer.
000164052 260__ $$aNew York [u.a.]$$bSpringer$$c2020
000164052 3367_ $$2DRIVER$$aarticle
000164052 3367_ $$2DataCite$$aOutput Types/Journal article
000164052 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1609155089_26352
000164052 3367_ $$2BibTeX$$aARTICLE
000164052 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164052 3367_ $$00$$2EndNote$$aJournal Article
000164052 500__ $$a2020 Dec;22(6):1495-1500
000164052 520__ $$aQuinoline-based ligands targeting cancer-associated fibroblasts have emerged as promising radiopharmaceuticals in different tumor entities. The aim of this retrospective study was to explore the potential of FAPI-PET/CT in the initial staging of esophageal cancer patients and its usefulness in radiotherapy planning as a first clinical analysis.Seven patients with treatment-naive esophageal cancer underwent FAPI-PET/CT. Tracer uptake was quantified by standardized uptake values (SUV)max and (SUV)mean. Six patients received definitive and one neoadjuvant (chemo)radiation therapy. Endo-esophageal clipping, the gold standard to define tumor margins not delineable per CT, was performed in three patients.Primary tumors demonstrated high FAPI uptake with a median SUVmax of 17.2. Excellent tumor-to-background ratios resulted in accurate target volume delineation and were found in perfect match with clipping. Detection of regional lymph node metastases facilitated the use of simultaneous integrated boost radiotherapy plans for these patients.FAPI-PET/CT may be beneficial for the management of esophageal cancer particularly in planning radiotherapy, but further research is necessary to increase patient number and statistical reliability.
000164052 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000164052 542__ $$2Crossref$$i2020-10-15$$uhttps://creativecommons.org/licenses/by/4.0
000164052 542__ $$2Crossref$$i2020-10-15$$uhttps://creativecommons.org/licenses/by/4.0
000164052 588__ $$aDataset connected to CrossRef, PubMed,
000164052 7001_ $$0P:(DE-HGF)0$$aGiesel, F. L.$$b1
000164052 7001_ $$0P:(DE-HGF)0$$aHaefner, M. F.$$b2
000164052 7001_ $$aStaudinger, F.$$b3
000164052 7001_ $$aLindner, T.$$b4
000164052 7001_ $$aMerkel, A.$$b5
000164052 7001_ $$aSchlittenhardt, J.$$b6
000164052 7001_ $$0P:(DE-HGF)0$$aKratochwil, C.$$b7
000164052 7001_ $$aChoyke, P. L.$$b8
000164052 7001_ $$0P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aHerfarth, K.$$b9$$udkfz
000164052 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, J.$$b10$$udkfz
000164052 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, U.$$b11$$udkfz
000164052 7001_ $$0P:(DE-HGF)0$$aKoerber, S. A.$$b12
000164052 77318 $$2Crossref$$3journal-article$$a10.1007/s11307-020-01548-y$$bSpringer Science and Business Media LLC$$d2020-10-15$$n6$$p1495-1500$$tMolecular Imaging and Biology$$v22$$x1536-1632$$y2020
000164052 773__ $$0PERI:(DE-600)2079211-6$$a10.1007/s11307-020-01548-y$$n6$$p1495-1500$$tMolecular imaging and biology$$v22$$x1536-1632$$y2020
000164052 909CO $$ooai:inrepo02.dkfz.de:164052$$pVDB
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000164052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000164052 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000164052 9141_ $$y2020
000164052 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-01-03$$wger
000164052 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL IMAGING BIOL : 2018$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-03
000164052 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-03
000164052 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x0
000164052 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x1
000164052 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x2
000164052 980__ $$ajournal
000164052 980__ $$aVDB
000164052 980__ $$aI:(DE-He78)HD01-20160331
000164052 980__ $$aI:(DE-He78)E060-20160331
000164052 980__ $$aI:(DE-He78)E050-20160331
000164052 980__ $$aUNRESTRICTED
000164052 999C5 $$1A Fiorentino$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.critrevonc.2019.03.008$$p117 -$$tCrit Rev Oncol Hematol$$uFiorentino A, Laudicella R, Ciurlia E, Annunziata S, Lancellotta V, Mapelli P, Tuscano C, Caobelli F, Evangelista L, Marino L, Quartuccio N, Fiore M, Borghetti P, Chiaravalloti A, Ricci M, Desideri I, Alongi P (2019) Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Crit Rev Oncol Hematol 139:117–124. https://doi.org/10.1016/j.critrevonc.2019.03.008$$v139$$y2019
000164052 999C5 $$1HL van Westreenen$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2004.01.083$$p3805 -$$tJ Clin Oncol$$uvan Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ et al (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22(18):3805–3812. https://doi.org/10.1200/JCO.2004.01.083$$v22$$y2004
000164052 999C5 $$1H Kato$$2Crossref$$9-- missing cx lookup --$$a10.1002/cncr.10330$$p921 -$$tCancer.$$uKato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 94(4):921–928$$v94$$y2002
000164052 999C5 $$2Crossref$$uZimmermann C, Babich JW, Joyal J, Marquis J, Wang J-C, inventors (2010) Molecular Insight Pharmaceuticals, Inc., assignee. Selective seprase inhibitors. U.S. patent application 2010/0098633 A1. April 22, 2010
000164052 999C5 $$1T Lindner$$2Crossref$$9-- missing cx lookup --$$a10.1186/s41181-019-0069-0$$p16 -$$tEJNMMI Radiopharm Chem$$uLindner T, Loktev A, Giesel F, Kratochwil C, Altmann A, Haberkorn U (2019) Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm Chem 4(1):16. https://doi.org/10.1186/s41181-019-0069-0$$v4$$y2019
000164052 999C5 $$1A Loktev$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.118.224469$$p1421 -$$tJ Nucl Med$$uLoktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marmé F, Jäger D, Mier W, Haberkorn U (2019) Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med 60(10):1421–1429. https://doi.org/10.2967/jnumed.118.224469$$v60$$y2019
000164052 999C5 $$1SA Koerber$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.119.237016$$p1331 -$$tJ Nucl Med$$uKoerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, Rathke H, Winter E, Lindner T, Syed M, Bhatti IA, Herfarth K, Choyke PL, Jaeger D, Haberkorn U, Debus J, Giesel FL (2020) The role of FAPI-PET/CT for patients with malignancies of the lower gastrointestinal tract - first clinical experience. J Nucl Med 61:1331–1336. https://doi.org/10.2967/jnumed.119.237016$$v61$$y2020
000164052 999C5 $$1T Lindner$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.118.210443$$p1415 -$$tJ Nucl Med$$uLindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, Jäger D, Mier W, Haberkorn U (2018) Development of Quinoline-based Theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 59(9):1415–1422. https://doi.org/10.2967/jnumed.118.210443$$v59$$y2018
000164052 999C5 $$1A Loktev$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.118.210435$$p1423 -$$tJ Nucl Med$$uLoktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D et al (2018) A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med 59(9):1423–1429. https://doi.org/10.2967/jnumed.118.210435$$v59$$y2018
000164052 999C5 $$1FL Giesel$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.118.215913$$p386 -$$tJ Nucl Med$$uGiesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U (2019) (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med 60(3):386–392. https://doi.org/10.2967/jnumed.118.215913$$v60$$y2019
000164052 999C5 $$1C Kratochwil$$2Crossref$$9-- missing cx lookup --$$a10.2967/jnumed.119.227967$$p801 -$$tJ Nucl Med$$uKratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL (2019) (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60(6):801–805. https://doi.org/10.2967/jnumed.119.227967$$v60$$y2019
000164052 999C5 $$1RL Siegel$$2Crossref$$9-- missing cx lookup --$$a10.3322/caac.21551$$p7 -$$tCA Cancer J Clin$$uSiegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551$$v69$$y2019
000164052 999C5 $$1CY Chen$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.radonc.2016.04.042$$p136 -$$tRadiother Oncol$$uChen CY, Li CC, Chien CR (2016) Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol 120(1):136–139. https://doi.org/10.1016/j.radonc.2016.04.042$$v120$$y2016
000164052 999C5 $$1H Chen$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00259-020-04769-z$$p1820 -$$tEur J Nucl Med Mol Imaging$$uChen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H (2020) Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47:1820–1832. https://doi.org/10.1007/s00259-020-04769-z$$v47$$y2020
000164052 999C5 $$1C Love$$2Crossref$$9-- missing cx lookup --$$a10.1148/rg.255045122$$p1357 -$$tRadiographics.$$uLove C, Tomas MB, Tronco GG, Palestro CJ (2005) FDG PET of infection and inflammation. Radiographics. 25(5):1357–1368. https://doi.org/10.1148/rg.255045122$$v25$$y2005
000164052 999C5 $$1S Uitte de Willige$$2Crossref$$9-- missing cx lookup --$$a10.1111/jth.12396$$p2029 -$$tJ Thromb Haemost$$uUitte de Willige S, Malfliet JJ, Janssen HL, Leebeek FW, Rijken DC (2013) Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis. J Thromb Haemost 11(11):2029–2036. https://doi.org/10.1111/jth.12396$$v11$$y2013
000164052 999C5 $$1C Egger$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ejphar.2017.05.022$$p64 -$$tEur J Pharmacol$$uEgger C, Cannet C, Gerard C, Suply T, Ksiazek I, Jarman E et al (2017) Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol 809:64–72. https://doi.org/10.1016/j.ejphar.2017.05.022$$v809$$y2017